Contraception
Volume 81, Issue 3 , Pages 215-222 , March 2010

Bleeding patterns and menstrual-related symptoms with the continuous use of a contraceptive combination of ethinylestradiol and drospirenone: a randomized study

  • Rogério Bonassi Machado

      Affiliations

    • Department of Obstetrics and Gynecology, Jundiaí School of Medicine, 13202-550 Jundiaí, São Paulo, Brazil
    • Corresponding Author InformationCorresponding author. Departamento de Ginecologia e Obstetrícia, Faculdade de Medicina de Jundiaí, 12202-550 Jundiaí, São Paulo, Brazil. Tel.: +55 11 4521 6466; fax: +55 11 4521 6040.
    • ,
  • Nilson Roberto de Melo

      Affiliations

    • Department of Obstetrics and Gynecology, School of Medicine, University of São Paulo, 05403-900 São Paulo, Brazil
    • ,
  • Hugo Maia Jr.

      Affiliations

    • Centro de Pesquisa e Assistência em Reprodução Humana (CEPARH), 44015-340 Salvador, Bahia, Brazil

Received 9 June 2009 ,Revised 9 September 2009 ,Accepted 27 October 2009.

References 

  1. Nelson AL. Extended-cycle oral contraception: a new option for routine use. Treat Endocrinol. 2005;4:139–145
  2. Edelman A, Gallo MF, Nichols MD, Jensen JT, Schulz KF, Grimes DA. Continuous versus cyclic use of combined oral contraceptives for contraception: systematic Cochrane review of randomized controlled trials. Hum Reprod. 2006;21:573–578
  3. Sulak PJ, Kuehl TJ, Coffee A, Willis S. Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen. Am J Obstet Gynecol. 2006;195:935–941
  4. den Tonkelaar I, Oddens BJ. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception. 1999;59:357–362
  5. Sulak PJ, Cressman BE, Waldrop E, Holleman S, Kuehl TJ. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet Gynecol. 1997;89:179–183
  6. Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol. 2000;95:261–266
  7. Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception. 2003;68:89–96
  8. Edelman A. Menstrual nirvana: amenorrhea through the use of continuous oral contraceptives. Curr Women's Health Rep. 2002;2:434–438
  9. Miller L, Hughes JP. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol. 2003;101:653–661
  10. Kwiecien M, Edelman A, Nichols MD, Jensen JT. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. Contraception. 2003;67:9–13
  11. Apter D, Borsos A, Baumgärtner W, et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contracept Reprod Health Care. 2003;8:37–51
  12. Sillem M, Schneidereit R, Heithecker R, Mueck AO. Use of an oral contraceptive containing drospirenone in an extended regimen. Eur J Contracept Reprod Health Care. 2003;8:162–169
  13. Sulak P, Willis S, Kuehl T, Coffee A, Clark J. Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval. Headache. 2007;47:27–37
  14. Coffee AL, Sulak PJ, Kuehl TJ. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Contraception. 2007;75:444–449
  15. Edelman AB, Koontz SL, Nichols MD, Jensen JT. Continuous oral contraceptives: are bleeding patterns dependent on the hormones given?. Obstet Gynecol. 2006;107:657–665
  16. Archer DF, Jensen JT, Johnson JV, Borisute H, Grubb GS, Constantine GD. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: Phase 3 study results. Contraception. 2006;74:439–445
  17. Machado RB, Fabrini P, Cruz AM, Maia E, da Cunha Bastos A. Clinical and metabolic aspects of the continuous use of a contraceptive association of ethinyl estradiol (30 microg) and gestodene (75 microg). Contraception. 2004;70:365–370
  18. Foidart JM, Wuttke W, Bouw GM, Gerlinger C, Heithecker R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care. 2000;5:124–134
  19. Huber J, Foidart JM, Wuttke W, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care. 2000;5:25–34
  20. Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low- dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception. 2000;61:105–111

PII: S0010-7824(09)00456-9

doi: 10.1016/j.contraception.2009.10.010

Contraception
Volume 81, Issue 3 , Pages 215-222 , March 2010

Article Tools

* Image Usage & Resolution